Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jesse D. Ortendahl, Amanda L. Harmon, Tanya G. K. Bentley & Michael S. Broder. (2017) A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies. Journal of Medical Economics 20:7, pages 767-775.
Read now
Read now
Julia F. Slejko, Robert L. Page$suffix/text()$suffix/text() & Patrick W. Sullivan. (2010) Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Current Medical Research and Opinion 26:10, pages 2485-2497.
Read now
Read now
Janne A. Martikainen, Erkki Soini & Thomas Paulsson. (2010) Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden. Current Medical Research and Opinion 26:2, pages 389-396.
Read now
Read now
Erkki J.O. Soini, Glenn Davies, Janne A. Martikainen, Henry X. Hu, Kaan Tunceli & Leo Niskanen. (2010) Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Current Medical Research and Opinion 26:1, pages 25-36.
Read now
Read now
Sandrin C. Bergheanu, Theo Reijmers, Aeilko H. Zwinderman, Ivana Bobeldijk, Raymond Ramaker, An-Ho Liem, Jan van der Greef, Thomas Hankemeier & J. Wouter Jukema. (2008) Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Current Medical Research and Opinion 24:9, pages 2477-2487.
Read now
Read now
Articles from other publishers (16)
Yrjänä Hynninen, Eeva Vilkkumaa & Ahti Salo. (2020) Operationalization of Utilitarian and Egalitarian Objectives for Optimal Allocation of Health Care Resources. Decision Sciences 52:5, pages 1169-1208.
Crossref
Crossref
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference, Ian M Graham, Alison Halliday, Ulf Landmesser, Borislava Mihaylova, Terje R Pedersen, Gabriele Riccardi, Dimitrios J Richter, Marc S Sabatine, Marja-Riitta Taskinen, Lale Tokgozoglu, Olov Wiklund, Christian Mueller, Heinz Drexel, Victor Aboyans, Alberto Corsini, Wolfram Doehner, Michel Farnier, Bruna Gigante, Meral Kayikcioglu, Goran Krstacic, Ekaterini Lambrinou, Basil S Lewis, Josep Masip, Philippe Moulin, Steffen Petersen, Anna Sonia Petronio, Massimo Francesco Piepoli, Xavier Pintó, Lorenz Räber, Kausik K Ray, Željko Reiner, Walter F Riesen, Marco Roffi, Jean-Paul Schmid, Evgeny Shlyakhto, Iain A Simpson, Erik Stroes, Isabella Sudano, Alexandros D Tselepis, Margus Viigimaa, Cecile Vindis, Alexander Vonbank, Michal Vrablik, Mislav Vrsalovic, José Luis Zamorano, Jean-Philippe Collet, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference, Ian M Graham, Alison Halliday, Ulf Landmesser, Borislava Mihaylova, Terje R Pedersen, Gabriele Riccardi, Dimitrios J Richter, Marc S Sabatine, Marja-Riitta Taskinen, Lale Tokgozoglu, Olov Wiklund, Stephan Windecker, Victor Aboyans, Colin Baigent, Jean-Philippe Collet, Veronica Dean, Victoria Delgado, Donna Fitzsimons, Chris P Gale, Diederick Grobbee, Sigrun Halvorsen, Gerhard Hindricks, Bernard Iung, Peter Jüni, Hugo A Katus, Ulf Landmesser, Christophe Leclercq, Maddalena Lettino, Basil S Lewis, Bela Merkely, Christian Mueller, Steffen Petersen, Anna Sonia Petronio, Dimitrios J Richter, Marco Roffi, Evgeny Shlyakhto, Iain A Simpson, Miguel Sousa-Uva, Rhian M Touyz, Djamaleddine Nibouche, Parounak H Zelveian, Peter Siostrzonek, Ruslan Najafov, Philippe van de Borne, Belma Pojskic, Arman Postadzhiyan, Lambros Kypris, Jindřich Špinar, Mogens Lytken Larsen, Hesham Salah Eldin, Margus Viigimaa, Timo E Strandberg, Jean Ferrières, Rusudan Agladze, Ulrich Laufs, Loukianos Rallidis, László Bajnok, Thorbjörn Gudjónsson, Vincent Maher, Yaakov Henkin, Michele Massimo Gulizia, Aisulu Mussagaliyeva, Gani Bajraktari, Alina Kerimkulova, Gustavs Latkovskis, Omar Hamoui, Rimvydas Slapikas, Laurent Visser, Philip Dingli, Victoria Ivanov, Aneta Boskovic, Mbarek Nazzi, Frank Visseren, Irena Mitevska, Kjetil Retterstøl, Piotr Jankowski, Ricardo Fontes-Carvalho, Dan Gaita, Marat Ezhov, Marina Foscoli, Vojislav Giga, Daniel Pella, Zlatko Fras, Leopoldo Perez de Isla, Emil Hagström, Roger Lehmann, Leila Abid, Oner Ozdogan, Olena Mitchenko & Riyaz S Patel. (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 41:1, pages 111-188.
Crossref
Crossref
François Mach, Colin Baigent, Alberico L. Catapano, Konstantinos C. Koskinas, Manuela Casula, Lina Badimon, M. John Chapman, Guy G. De Backer, Victoria Delgado, Brian A. Ference, Ian M. Graham, Alison Halliday, Ulf Landmesser, Borislava Mihaylova, Terje R. Pedersen, Gabriele Riccardi, Dimitrios J. Richter, Marc S. Sabatine, Marja-Riitta Taskinen, Lale Tokgozoglu, Olov Wiklund, Stephan Windecker, Victor Aboyans, Colin Baigent, Jean-Philippe Collet, Veronica Dean, Victoria Delgado, Donna Fitzsimons, Chris P. Gale, Diederick Grobbee, Sigrun Halvorsen, Gerhard Hindricks, Bernard Iung, Peter Jüni, Hugo A. Katus, Ulf Landmesser, Christophe Leclercq, Maddalena Lettino, Basil S. Lewis, Bela Merkely, Christian Mueller, Steffen Petersen, Anna Sonia Petronio, Dimitrios J. Richter, Marco Roffi, Evgeny Shlyakhto, Iain A. Simpson, Miguel Sousa-Uva, Rhian M. Touyz, Djamaleddine Nibouche, Parounak H. Zelveian, Peter Siostrzonek, Ruslan Najafov, Philippe van de Borne, Belma Pojskic, Arman Postadzhiyan, Lambros Kypris, Jindřich Špinar, Mogens Lytken Larsen, Hesham Salah Eldin, Margus Viigimaa, Timo E. Strandberg, Jean Ferrières, Rusudan Agladze, Ulrich Laufs, Loukianos Rallidis, László Bajnok, Thorbjörn Gudjónsson, Vincent Maher, Yaakov Henkin, Michele Massimo Gulizia, Aisulu Mussagaliyeva, Gani Bajraktari, Alina Kerimkulova, Gustavs Latkovskis, Omar Hamoui, Rimvydas Slapikas, Laurent Visser, Philip Dingli, Victoria Ivanov, Aneta Boskovic, Mbarek Nazzi, Frank Visseren, Irena Mitevska, Kjetil Retterstøl, Piotr Jankowski, Ricardo Fontes-Carvalho, Dan Gaita, Marat Ezhov, Marina Foscoli, Vojislav Giga, Daniel Pella, Zlatko Fras, Leopoldo Perez de Isla, Emil Hagström, Roger Lehmann, Leila Abid, Oner Ozdogan, Olena Mitchenko & Riyaz S. Patel. (2019) 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 290, pages 140-205.
Crossref
Crossref
Vasilii V. Simerzin, Margarita A. Krasovskaya & Anton V. Gagloev. (2019) RISK FACTORS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RISK STRATIFICATION AND TREATMENT TACTICS. Science and Innovations in Medicine 4:1, pages 20-25.
Crossref
Crossref
Yrjänä Hynninen, Miika Linna & Eeva Vilkkumaa. (2019) Value of genetic testing in the prevention of coronary heart disease events. PLOS ONE 14:1, pages e0210010.
Crossref
Crossref
Erkki Soini, Christian Asseburg, Maarit Taiha, Kari Puolakka, Oana Purcaru & Riitta Luosujärvi. (2017) Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland. Advances in Therapy 34:10, pages 2316-2332.
Crossref
Crossref
Esse I. H. Akpo, Irshaad R. Jansen, Edith Maes & Steven Simoens. (2017) Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer. Frontiers in Pharmacology 8.
Crossref
Crossref
Erkki Soini, Jaana Joutseno & Marja-Liisa Sumelahti. (2017) Cost-utility of First-line Disease-modifying Treatments for Relapsing–Remitting Multiple Sclerosis. Clinical Therapeutics 39:3, pages 537-557.e10.
Crossref
Crossref
Livio Garattini & Anna Padula. (2017) Cholesterol-lowering drugs: science and marketing. Journal of the Royal Society of Medicine 110:2, pages 57-64.
Crossref
Crossref
Adam D. M. Briggs, Jane Wolstenholme, Tony Blakely & Peter Scarborough. (2016) Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions. Population Health Metrics 14:1.
Crossref
Crossref
Alberico L. Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M. John Chapman, Heinz Drexel, Arno W. Hoes, Catriona S. Jennings, Ulf Landmesser, Terje R. Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W. M. Monique Verschuren, Charalambos Vlachopoulos, David A. Wood & Jose Luis Zamorano. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal 37:39, pages 2999-3058.
Crossref
Crossref
Alberico L. Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M. John Chapman, Heinz Drexel, Arno W. Hoes, Catriona S. Jennings, Ulf Landmesser, Terje R. Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W.M. Monique Verschuren, Charalambos Vlachopoulos, David A. Wood & Jose Luis Zamorano. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis 253, pages 281-344.
Crossref
Crossref
Emma Aarnio, Maarit J. Korhonen, Risto Huupponen & Janne Martikainen. (2015) Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence – Estimates from the Finnish prescription register. Atherosclerosis 239:1, pages 240-247.
Crossref
Crossref
J A Martikainen, E J O Soini, D E Laaksonen & L Niskanen. (2011) Health economic consequences of reducing salt intake and replacing saturated fat with polyunsaturated fat in the adult Finnish population: estimates based on the FINRISK and FINDIET studies. European Journal of Clinical Nutrition 65:10, pages 1148-1155.
Crossref
Crossref
Hye-Young Kang, Su-Kyoung Ko & Danny Liew. (2009) Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: The Korean Individual-Microsimulation Model for Cardiovascular Health Interventions. Clinical Therapeutics 31:12, pages 2919-2930.
Crossref
Crossref
Danny Liew, Hye-Jin Park & Su-Kyoung Ko. (2009) Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Clinical Therapeutics 31:10, pages 2189-2203.
Crossref
Crossref